Last reviewed · How we verify

NCT04670562

Longitudinal Follow up of Patients With Pleural Effusion

Status unknown Last updated 22 June 2022
What this trial tests

trial in Pleural Effusion, Malignant in 500 participants. Status unknown.

Timeline
1 March 2021
Primary endpoint
1 December 2024
31 December 2025

Quick facts

Lead sponsorSeoul National University Bundang Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 March 2021
Primary completion1 December 2024
Estimated completion31 December 2025
Sites1 location across South Korea

Conditions studied

Sponsor

Seoul National University Bundang Hospital

Who can join

Eligibility, any sex, with Pleural Effusion, Malignant or Prognosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the clinical course of patients diagnosed with pleural effusion and determine various clinical factors and biomarkers associated that can predict the diagnosis and clinical outcome and prognosis of patients with pleural effusion due to specific causes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pleural Effusion, Malignant

Currently open trials in the same condition.

Other Seoul National University Bundang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04670562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing